KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Randomized, Double-Blind, Multicenter, Phase 3 Study of AG NPP709 Compared With Ivy Leaf Extract in Patients With Acute or Chronic Respiratory Symptoms.

Young-Joo Cho, Ho Joo Yoon, Dae Hyun Lim, Kwang Ha Yoo, Sun-Hee Choi, Yeong-Ho Rha

J Korean Med Sci 41(9) e97

PMID41807028
PMCIDPMC12976630
DOI10.3346/jkms.2026.41.e97
发表日期2026-03-10
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Fig. 1:图注未提示 KM 曲线;Fig. 2:图注未提示 KM 曲线;Fig. 3:图注未提示 KM 曲线。
摘要

摘要

BACKGROUND: AG NPP709, formulated with extracts of ivy leaves and Coptis chinensis rhizomes, has antitussive and expectorant effects in preclinical rodent studies. We conducted a clinical trial to establish the efficacy and safety of the product compared with a widely prescribed ivy leaf extract product for the treatment of respiratory symptoms. METHODS: In this randomized, double-blind, active-controlled, non-inferiority phase 3 trial, conducted in six hospitals in South Korea, symptomatic patients with acute upper respiratory infections (URIs) or chronic inflammatory bronchitis were randomized to receive either AG NPP709 or ivy leaf extract (control drug) for 5 days (n = 118 in each group). The primary efficacy endpoint was the clinical improvement rate, defined as the percentage of patients with symptoms evaluated as the top two scores on a five-point Likert scale at the end of the study (with a non-inferiority margin set at -15.0%). RESULTS: The overall patient age ranged from 2 to 70 years, with a mean age of 24.9 years in the AG NPP709 group and 21.7 years in the control group. No statistical difference was observed in the clinical improvement rate, with a between-group difference of 4.3% (95% confidence interval: -8.9, 17.5). The symptom clearance rates (AG NPP709 vs. control) for cough and sputum were 43.0% vs. 40.0% (P = 0.655) and 34.6% vs. 25.5% (P = 0.142), respectively. The incidence of adverse events was similar in both groups (11.0% vs. 11.1%, P = 0.982), with most events being grade 1 or 2. CONCLUSION: AG NPP709 was non-inferior to ivy leaf extract and had an acceptable safety profile. AG NPP709 could be an alternative treatment option for alleviating the symptoms associated with acute URI and chronic bronchitis. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01151202.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Patient distribution. Six tertiary hospitals in the Republic of Korea participated in the trial. Eligible patients were randomized to AG NPP709, a combination of ivy leaf extract and Coptis chinensis rhizome extract, or control drug, ivy leaf extract, in a 1:1 ratio. ITT = intention-to-treat.
非 KM Figure
Fig. 2Clinical improvement rate in the per-protocol set ( A ) and intention-to-treat set ( B ). Among the five Likert scales used to assess clinical improvement, only completely resolved or greatly improved was considered a clinical improvement. The numbers inside the black square denote the clinical improvement rate in each group. Among 117 patients included in the intention-to-treat set of the control group, one patient without any patient diary record was excluded from the analysis.
非 KM Figure
Fig. 3Symptom clearance rate based on patient’s self-assessment. The symptom clearance rate is based on the patient’s self-assessment result. No significant between-group difference was observed in any of the symptoms in terms of symptom clearance rate.
非 KM Figure